

Imfinzi® (durvalumab) - New indication

- On December 5, 2024, <u>AstraZeneca announced</u> the <u>FDA approval</u> of <u>Imfinzi (durvalumab)</u>, as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT).
- Imfinzi is also approved, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
- In addition to small cell lung cancer, Imfinzi is approved for non-small cell lung cancer, biliary tract cancer, hepatocellular carcinoma, and endometrial cancer.
- The approval of Imfinzi for the new indication was based on ADRIATIC, a randomized, double-blind, placebo-controlled study in 530 patients with histologically or cytologically confirmed LS-SCLC whose disease had not progressed following cCRT. The major efficacy measures were overall survival (OS) and progression-free survival (PFS).
 - The median OS was 55.9 months with Imfinzi vs. 33.4 months with placebo (hazard ratio [HR] 0.73, 95% CI: 0.57, 0.93; p = 0.0104).
 - The median PFS was 16.6 months with Imfinzi vs. 9.2 months with placebo (HR 0.76, 95% CI: 0.61, 0.95; p = 0.0161).
- The recommended intravenous dose of Imfinzi for the treatment of LS-SCLC is 1,500 mg every 4 weeks for patients with a body weight of ≥ 30 kg and 20 mg/kg every 4 weeks for patients with a body weight of < 30 kg. Treatment should continue until disease progression, unacceptable toxicity, or a maximum of 24 months.
 - Refer to the Imfinzi drug label for dosing for all its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.